Qiming Venture Leads $30M Series A In ZAI Lab

Shanghai-based biotech drug company ZAI Lab has received US$30 million Series A financing led by Qiming Venture Partners, according to ZAI Lab’s official announcement. KPCB, Sequoia Capital and TF Capital also participate in this round of financing.

Tencent Injects $70M In Healthcare Portal DXY

China’s largest online healthcare community portal DXY, which is short for its Chinese name Ding Xiang Yuan, has received US$70 million series C financing from Tencent Holdings Limited, according to an official announcement. The details of the investment are not disclosed, but Tencent will take a "small proportion" of the company, according to the statement.

OrbiMed Raises $325M For Its Second Asian Fund

Healthcare-dedicated investment firm OrbiMed Advisors has closed a US$325 million Asian fund, above its US$300 million target and much larger than its first Asian vehicle with US$188 million launched in 2008, according to media reports. The new fund is to focus on investing in drug developers, diagnostics firms and medical device manufacturers in the region.

Cathay Capital Invest $24.5M In Kunming Shenghuo Pharma

Sino-French private equity firm Cathay Capital Private Equity says it has invested RMB150 million (US$24.5 million) in traditional Chinese medicine firm Kunming Shenghuo Pharmaceutical Group Co., Ltd., according to a company announcement. The deal was closed at the end of June. The investment is from Cathay Capital II and the Sino-French Fund for small and medium enterprises (SMEs)

Harvard Medical School, Others To Inject $1.3B To Build Shenzhen Hospitals

Twenty-four domestic and international investors and institutions plan to sign an agreement next Monday with the government of Shenzhen, to invest a total of RMB8 billion (US$1.3B) to build private and public hospitals in the city, according to Chinese media reports. The planned investment is part of the drive initiated by the Chinese government since the 2009 healthcare reform to attract more private capital into the sector.

Xiaomi Ventures To Invest $25M In Andon Health

Chinese smartphone maker Xiaomi Inc.‘s venture capital arm has agreed to invest US$25 million in Chinese health products maker Andon Health Company Limited, according to a regulatory filing. Tianjin-based Andon Health will establish a new entity called iHealth Inc. in Cayman Island, and inject its related global businesses in electronic and smart health device division iHealth into the new platform. Xiaomi Ventures Limited will hold a 20% stake of iHealth Inc. The two will develop new health products and services …

CVC Makes Partial Exit From Jintian Pharmaceutical Group

London-based US$46 billion-under-management private equity firm CVC Capital Partners is selling 186 million shares in China’s Jintian Pharmaceutical Group for as much as HK$620 million (US$79.95 million), according to media reports. CVC is selling the shares in a range of HK$3.29 to HK$3.34 apiece, representing a 3.5% to 4.9% discount to the share’s last closing price.

Tencent Leads $100M Financing Round For GuaHao.Com

Hangzhou-based online healthcare service provider GuaHao.com has received over US$100 million investment by Chinese Internet services giant Tencent Holdings Limited, according to a company announcement. This is the largest single investment in China’s Internet healthcare sector. No further details of the investment were disclosed. But GuaHao.com will continue to operate independently, says the statement. The investment is part of a wider strategic partnership to be established between the two parties. GuaHao.com will incorporate Tencent’s products such as its Wechat app …

Sailing Capital Invests $50M In UK’s Enigma Diagnostics

Salisbury, U.K.-based molecular diagnostic testing firm Enigma Diagnostics Ltd. says that Sailing Capital Management has agreed to invest US$50 million to help support the British company’s global expansion, according to a company announcement. Sailing Capital is an investment firm controlled by Shanghai International Group (SIG). Last December, it launched a RMB5 billion buyout fund to focus on cross-border deals, and a RMB5 billion ($821m) buyout fund.

Luye Pharma Acquires Remaining Stake Of Beijing Jialin

Yantai, Shandong Province-based Chinese drug-maker Luye Pharma Group Ltd., backed by Chinese private equity investors, has agreed to acquire the remaining 42.02% stake of Beijing Jialin Pharmaceutical Co., Ltd. it doesn’t already own, according to a regulatory filing submitted on October 24. Luye Pharma, with shareholders including CDH Investments, CITIC Private Equity and New Horizon Capital, just completed a Hong Kong IPO in July raising a total of US$764 million.

China To Become World’s Second Largest Medtech Market By 2020

China’s medical technology (medtech) market will grow at 14% compound annual growth rate from 2013 to 2020 to reach US$55 million in total size by 2020, making it the world’s second largest medtech market, says a new report released by The Boston Consulting Group. China’s healthcare reform has significantly transformed the healthcare system, including changing regulatory policies, intensifying pricing pressure, and broadening reimbursement coverage.

BVCF-Backed Jaguar Animal Health Plans $54M US IPO

San Francisco-based veterinary drug developer Jaguar Animal Health Inc., backed by China-focused life sciences private equity investor BVCF, is planning an IPO on the NASDAQ to raise as much as US$54 million, according to a regulatory filing. The company is planing to sell five million shares at an indicative price range of of US$7 to US$9 apiece.

Chindex Completes Go-Private Deal By TPG, Fosun

NASDAQ-listed Chinese high-end hospital operator Chindex International, Inc. says that it has completed a go-private transaction by an investor consortium for US$24 per share in cash, according to a company announcement. The company has been acquired by Healthy Harmony Holdings, L.P., an affiliate of TPG Capital, Shanghai Fosun Pharmaceutical (Group) Co., Ltd., and Chindex’s CEO, Roberta Lipson.